Brian J. Brille - 15 May 2026 Form 4 Insider Report for Caris Life Sciences, Inc. (CAI)

Reporting relationship: Vice Chairman and Executive Vice President, Director
Issuer ticker: CAI
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2026, 16:23:02 UTC
Prior SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

Brian J. Brille filed Form 4 for Caris Life Sciences, Inc. (CAI) on 18 May 2026.

Key facts

This page summarizes Brian J. Brille's Form 4 filing for Caris Life Sciences, Inc. (CAI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 May 2026, 16:23.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0002071959 Primary reporting owner

Relationship: Vice Chairman and Executive Vice President, Director
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 18 May 2026

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Tax liability

CAI holding

No transaction description listed

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 3 footnotes

Footnote F1

Shares withheld for the payment of taxes on the vesting and settlement of RSUs.

Footnote F2

The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Footnote F3

By a family trust, with shares previously held in multiple family trusts consolidated into a single trust.

SEC remarks

Vice Chairman and Executive Vice President